Autor: |
Brown, Andrew C., Baigent, Susan J., Smith, Lorraine P., Chattoo, Jason P., Petherbridge, Lawrence J., Hawes, Pippa, Allday, Martin J., Nair, Venugopal |
Předmět: |
|
Zdroj: |
Proceedings of the National Academy of Sciences of the United States of America; 2/7/2006, Vol. 103 Issue 6, p1687-1692, 6p |
Abstrakt: |
Marek's disease virus (MDV) is an oncogenic herpesvirus that induces fatal T cell lymphomas in chickens. With more than 20 billion doses of vaccine used annually, vaccination constitutes the cornerstone of Marek's disease control. Despite the success of vaccination, evolution of virulence among MDV strains continues to threaten the effectiveness of the current Marek's disease vac- cines. MDV-encoded protein MEQ (MDV EcoRl Q) probably acts as a transcription factor and is considered to be the major MDV oncoprotein. MEQ sequence shows a Pro-Leu-Asp-Leu-Ser (PLDLS) motif known to bind C-terminal-binding protein (CtBP), a highly conserved cellular transcriptional corepressor with roles in the regulation of development, proliferation, and apoptosis. Here we show that MEQ can physically and functionally interact with CtBP through this motif and that this interaction is critical for oncogen- esis because mutations in the CtBP-interaction domain completely abolished oncogenicity. This direct role for MEQ-CtBP interaction in MDV oncogenicity highlights the convergent evolution of mo- lecular mechanisms of neoplastic transformation by herpesviruses because Epstein-Barr virus oncoproteins EBNA 3A and 3C also interact with CtBP. We also demonstrate that the nononcogenic MDV generated by mutagenesis of the CtBP-interaction domain of MEQ has the potential to be an improved vaccine against virulent MDV infection. Engineering MDV with precisely defined attenuat- ing mutations, therefore, represents an effective strategy for generating new vaccines against this major poultry disease. [ABSTRACT FROM AUTHOR] |
Databáze: |
Complementary Index |
Externí odkaz: |
|